In an oversubscribed Series D funding round sponsored by Premji Invest, BillionToOne, a molecular diagnostics company, has secured $130 million in funding. Neuberger Berman, Adam Street Partners, and Baillie Gifford are among the existing investors who participated. This latest investment brings the company's total capital raised to nearly $400 million and will be used to scale its prenatal and oncology businesses. BillionToOne’s Quantitative Counting Templates (QCTs) technology, which enables single base-pair precision DNA molecule counting, has driven substantial growth, reaching $125 million in annual recurring revenue in four years.
BillionToOne’s offerings include the UNITY Fetal Risk Screen, a prenatal test that assesses fetal risk for aneuploidies and inherited conditions without invasive procedures, and oncology liquid biopsy products Northstar Select and Northstar Response. Northstar Select offers a lower detection limit than other assays, while Northstar Response provides high precision in monitoring late-stage cancer treatment responses. Headquartered in Menlo Park, California, BillionToOne aims to make molecular diagnostics more powerful, efficient, and accessible, with its patented QCT technology positioning it at the forefront of precision diagnostics.
